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Enzymes are proteins that catalyze almost every 
chemical reaction in living systems, achieving 
rate enhancements of up to 21 orders of mag-
nitude relative to the uncatalyzed reactions. 
However, despite a century of intense investi-
gation, the biophysical basis of the enormous 
catalytic power of enzymes is not completely 
understood. Enzymes are not only central to 
living systems, but also to many industrial pro-
cesses such as the production of food, textiles, 
detergents, pharmaceuticals and other chemi-
cals where environmentally friendly, green 
methods are of ever increasing importance. 
Because of their central role for life, enzymes 
are key drug targets and enzyme inhibition is 
a central strategy in the design of new drugs. 
Acetylsalicylic acid, azidothymidine, acyclo-
vir, allopurinol, chloramphenicol, exemestane, 
fosfomycin, isoniazid, methotrexate, profens, 
proguanil, statins, thiouracil and warfarin are 
but a small subset of approved drug substances 
that are used in the clinic to treat, among oth-
ers, pain, fever, inflammation, malaria, cancer, 
HIV, bacterial and viral infections, rheuma-
toid arthritis, osteoarthritis and heart disease, 
through the inhibition of key enzymes.
In 1894 Emil Fischer (Nobel Prize in 
Chemistry 1902) proposed his lock-and-key 
model, which simply states that an enzyme’s 
active site complements its substrate in the 
same way as a lock complements its key, as a 
rationale for the catalytic power of enzymes [1]. 
This was adapted in 1930 by John Burdon 
Sanderson Haldane to include ground state 
destabilization (changes to the structure of the 
‘key’ when it enters the ‘lock’) [2]. Linus Paul-
ing (Nobel Prize in Chemistry 1952) incor-
porated transition state theory (TST), which 
had earlier been developed by Michael Polanyi 
and extended by Henry Eyring [3–5]. In TST, 
enzymatic rate accelerations are explained 
by the lowering of the transition state energy 
and/or increase of the ground state energy. 
TST has underpinned the design of transi-
tion state analogues for enzyme inhibition 
and the creation of catalytic antibodies. The 
rationale behind transition state analogues is 
that if enzymes have evolved to bind tightly to 
the transition state of a reaction then a stable 
but unreactive molecule that resembles this 
transition state will be a good inhibitor of the 
enzyme. Although the transition state is only 
transiently formed during the reaction and 
is not directly observable, information on its 
structure and electronic state may be probed 
by kinetic isotope effects, the ratio of the rate 
constants was obtained when isotopically 
labeled reactant molecules are used and those 
seen using reactant molecules with isotopes of 
natural abundance [6,7].
These theories did not incorporate dynam-
ics, despite the fact that enzymes are highly 
flexible molecules. Daniel E Koshland’s 
induced fit hypothesis accounted for large-
scale changes in enzyme structure on binding 
a substrate [8], and many enzymes adopt differ-
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“...the combination of chemical ligation and heavy enzyme 
approaches can be applied to a wide range of pharmaceutically and 
industrially important enzymes, and will lead to new candidates for 
biological and medical applications, as well as new production routes 
for enzymes of industrial use.”
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ent conformations as they move through their catalytic 
cycles [9]. Because the electrostatics of an enzyme deter-
mine the free energy surface, equilibrium motions reflect 
the change in interactions between the atoms as the 
enzyme moves across the free energy surface. Therefore, 
while it is generally accepted that electrostatic preorga-
nization plays the dominant role in enzyme catalysis [10], 
studies of the motions of an enzyme provide central 
information about the nature of its energy ‘landscape’.
Recently, Vern Schramm’s laboratory at Albert 
Einstein College of Medicine, New York, pioneered 
the use of ‘heavy enzymes’ to probe enzyme dynam-
ics. In their approach >98% of the carbon, nitrogen 
and nonexchangeable hydrogen atoms of an enzyme 
are replaced with the corresponding stable heavy iso-
topes 13C, 15N and 2H, leading to a molecular weight 
increase of ∼10%, and the catalytic properties of this 
heavy enzyme are compared with the natural light ver-
sion [11,12]. Isotope substitution does not change the 
chemistry of the catalyzed reaction but slows motions 
of the catalyst, from femtosecond bond vibrational fre-
quencies through millisecond conformational changes 
to slow domain rearrangements. Hence, the entire pro-
file of motions of an enzyme can be altered and investi-
gated by isotopic substitution. The ratio of the reaction 
rate constants of the ‘heavy’ enzyme and the ‘light’ 
enzyme therefore provides information on the degree 
of motional coupling to the reaction.
We have applied heavy enzyme methodology to the 
reaction catalyzed by the enzyme dihydrofolate reduc-
tase (DHFR), a vital biosynthetic enzyme required 
for the production of DNA and a number of amino 
acids. By combining experimental heavy enzyme mea-
surements to detect motional coupling with computa-
tional studies to understand the underlying molecu-
lar mechanism, we have demonstrated not only that 
slower DHFR motions couple to substrate binding 
and product release, which showed that these motions 
are important for progression through the catalytic 
cycle [13,14], but also that femtosecond bond vibrations 
couple directly to transition state formation [15–18]. 
However, we found the coupling of bond vibrations 
to the actual chemical reaction to be detrimental for 
DHFR catalysis [15]. Indeed, dihydrofolate reductases 
from across a range of organisms appear to minimize 
fast dynamic coupling under conditions most represen-
tative of their physiological niches, but with elevated 
dynamic coupling seen under nonphysiological condi-
tions [18] and in variant enzymes [16]. These apparently 
contradictory results demonstrate the delicate nature 
of motional coupling to catalysis. We have refined this 
global picture of motional coupling by isotopically 
labeling specific segments of an enzyme and there-
fore experimentally determining which parts of the 
enzyme show motional coupling [19]. Two isotopic 
hybrids of DHFR were prepared by chemical ligation 
techniques [20], one in which the mobile N-terminal 
segment contained heavy isotopes while the remain-
der of the protein was of natural isotopic abundance, 
and one in which only the C-terminal region was iso-
topically labeled. These experiments revealed that the 
N-terminal region is only involved in beneficial milli-
second conformational motions, while in the C-termi-
nal region fast dynamic motions couple unfavorably to 
barrier crossing, thereby slowing the reaction [19]. The 
combination of chemical ligation and heavy enzyme 
approaches has shown for the first time that different 
parts of an enzyme affect different aspects of its func-
tion. Schramm has recently used labeling methodol-
ogy to determine which amino acid residue types have 
motions that couple to the reaction [21].
Much has been learned about Nature’s catalysts but 
much remains to be discovered before we can claim to 
fully understand the physical basis of enzyme catalysis. 
We are however now in a position where results from 
fundamental investigations can be used to drive the 
development of novel chemicals of societal use. Using 
kinetic isotope effects based on labeling the reactant 
molecules, Schramm et al. have mapped the transi-
tion state of purine nucleoside phosphorylase, a key 
enzyme involved in DNA recycling [22]. Synthesis of 
molecules based on this work has led to the produc-
tion of stable transition state analogues with several 
million-fold tighter binding to the enzyme than its 
natural substrates, and excellent selectivity between 
the enzymes from human and the malaria parasite 
Plasmodium falciparum [23,24]. Heavy enzyme meth-
odology, based on labeling of the enzyme itself, has 
revealed the involvement of fast enzyme motions in 
forming the transition state of the reaction [11]. These 
two complementary techniques each provide a poten-
tial route to new enzyme inhibitors that may be used 
as drugs (Figure 1).
The central role of DHFR in metabolism means that 
it has long been a valuable target for drugs such as the 
antibacterial trimethoprim, the antimalarial pyrimeth-
amine and the clinically highly successful anticancer 
agent methotrexate. DHFR has recently attracted 
renewed attention to overcome resistance now seen 
against existing drugs and to reduce side-effects by 
increasing selectivity. It has been suggested that inhibi-
“The central role of DHFR in metabolism means 
that it has long been a valuable target for drugs 
such as the antibacterial trimethoprim, the 
antimalarial pyrimethamine and the clinically 
highly successful anticancer agent methotrexate.”
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tors of enzyme motions crucial for an enzyme’s cata-
lytic cycle can be designed and used as new therapeu-
tics [25]. Therefore, in addition to designing transition 
state analogues based on traditional kinetic isotope 
effect methods, the combination of chemical ligation 
and heavy enzyme approaches may allow the construc-
tion of a new tool for drug design and development, 
as understanding the nature and location of coupling 
between the motions of an enzyme and bound mol-
ecules will assist in the design of ‘allosteric inhibi-
tors’ that bind to more remote regions of the enzyme 
but prevent motions important for the catalytic cycle 
(Figure 1). Whereas a transition state analogue places 
the enzyme in an energy well too deep for it to readily 
escape, an allosteric inhibitor alters the energy barri-
ers to conformational change and so blocks productive 
progression through the catalytic cycle. Because heavy 
enzyme approaches can distinguish motions that are 
involved solely in conformational changes from those 
involved in transition state formation [19], the two 
classes of motion may be targeted separately (Figure 1). 
More generally, the combination of chemical ligation 
and heavy enzyme approaches can be applied to a wide 
range of pharmaceutically and industrially important 
enzymes, and will lead to new candidates for biological 
and medical applications, as well as new production 
Figure 1. Complementary approaches to enzyme inhibition. (A) Use of isotope labeling methodologies to 
generate transition state analogues and allosteric inhibitors. (B) Energy landscape of a model enzymatic reaction 
(black) showing changes in the presence of allosteric inhibitors targeting conformational changes (blue) and 
transition state formation (red).
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routes for enzymes of industrial use. Most importantly, 
it demonstrates how bringing together different experi-
mental and computational methods to address some 
of the most challenging problems in modern enzymol-
ogy can generate applications in medicine with wide 
societal benefits.
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